Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 15/20 | 0.69 |
| ▸ | BRAF | P15056 | 9/20 | 0.69 |
| ▸ | KDR | P35968 | 5/20 | 0.69 |
| ▸ | RET | P07949 | 3/20 | 0.69 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.69 |
| ▸ | ABL1 | P00519 | 2/20 | 0.69 |
| ▸ | HTR1A | P08908 | 2/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.69 |
| ▸ | KIT | P10721 | 2/20 | 0.69 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.69 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.69 |
| ▸ | FLT1 | P17948 | 2/20 | 0.69 |
| ▸ | MAOA | P21397 | 2/20 | 0.69 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.69 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.69 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.69 |
| ▸ | TTK | P33981 | 2/20 | 0.69 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL694648 | 0.93 | RAF1 (0.67) | RAF1BRAFKDRRETRIPK2 | |
| Hydrochloric Acid SCHEMBL1702120 | 0.92 | RAF1 (0.66) | RAF1BRAFKDRRETRIPK2 | |
| Hydrochloric Acid SCHEMBL1702492 | 0.91 | RAF1 (0.65) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL1702479 | 0.89 | RAF1 (0.63) | RAF1BRAFKDRRETRIPK2 | |
| Sulfuric Acid SCHEMBL2043327 | 0.89 | RAF1 (0.63) | RAF1BRAFKDRRETRIPK2 | |
| Maleic Acid SCHEMBL1702367 | 0.88 | RAF1 (0.61) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL2045624 | 0.87 | RAF1 (0.60) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL6012038 | 0.86 | RAF1 (0.61) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL14481187 | 0.86 | RAF1 (0.59) | RAF1BRAFKDRRETRIPK2 | |
| Sorafenib SCHEMBL16699243 | 0.86 | RAF1 (0.81) | RAF1BRAFKDRRETRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210113614-A1 | COMBINATION OF CELLULAR IMMUNOTHERAPY | CARSGEN THERAPEUTICS CO., LTD. (CN) | 2021-04-22 | — | — | US | claimed |
| EP-3747433-A1 | COMBINATION OF CELLULAR IMMUNOTHERAPY | Carsgen Therapeutics Co., Ltd. (CN) | 2020-12-09 | — | — | EP | claimed |
| WO-2019149279-A1 | COMBINATION OF CELLULAR IMMUNOTHERAPY | 科济生物医药（上海）有限公司 | 2019-08-08 | — | — | WO | claimed |
| US-8637553-B2 | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions | BAYER HEALTHCARE LLC (US) | 2014-01-28 | — | — | US | claimed |
| CN-1856469-B | Fluoro omega-carboxyaryl diphenyl ureas for the treatment and prevention of diseases and disease symptoms | BAYER PHARMACEUTICALS CORP | 2013-03-06 | — | — | CN | claimed |
| CN-102816113-A | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions | BAYER PHARMACEUTICALS CORP | 2012-12-12 | — | — | CN | claimed |
| EP-1636585-B2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-06-13 | — | — | EP | claimed |
| EP-1636585-B1 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORP (US) | 2008-01-16 | — | — | EP | claimed |
| EP-1663978-B1 | FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS | BAYER PHARMACEUTICALS CORP (US) | 2007-11-28 | — | — | EP | claimed |
| EP-1626714-B1 | DIARYL UREAS FOR DISEASES MEDIATED BY PDGFR | BAYER PHARMACEUTICALS CORP (US) | 2007-07-04 | — | — | EP | claimed |
| JP-2006528196-A | — | — | 2006-12-14 | — | — | JP | claimed |
| EP-1663978-A2 | FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS | Bayer Pharmaceuticals Corporation (US) | 2006-06-07 | — | — | EP | claimed |
| EP-1626714-A2 | DIARYL UREAS FOR DISEASES MEDIATED BY PDGFR | Bayer Pharmaceuticals Corporation (US) | 2006-02-22 | — | — | EP | claimed |
| US-20050059703-A1 | Treating, ameliorating, preventing, or modulating restenosis following angioplastic surgery, injure the vascular system; a salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea; intravascular stent is impregnated with the compound to inhibit restenosis | BAYER HEALTHCARE LLC | 2005-03-17 | — | — | US | claimed |
| US-20050038080-A1 | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions | BAYER HEALTHCARE LLC | 2005-02-17 | — | — | US | claimed |
| WO-2005009961-A2 | FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-02-03 | — | — | WO | claimed |
| WO-2005000284-A2 | DIARYL UREAS FOR DISEASES MEDIATED BY PDGFR | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-01-06 | — | — | WO | claimed |
| CN-117917399-A | Preparation method of regorafenib crystal form I | 重庆药友制药有限责任公司 | 2024-04-23 | — | — | CN | disclosed |
| EP-3747433-A1 | COMBINATION OF CELLULAR IMMUNOTHERAPY | Carsgen Therapeutics Co., Ltd. (CN) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019149279-A1 | COMBINATION OF CELLULAR IMMUNOTHERAPY | 科济生物医药（上海）有限公司 | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059703-A1 | Treating, ameliorating, preventing, or modulating restenosis following angioplastic surgery, injure the vascular system; a salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea; intravascular stent is impregnated with the compound to inhibit restenosis | PDGFRB, PDGFRA, PDGFA | RAF1 761/4885BRAF 1489/4885KDR 14/4885 |
| US-20210113614-A1 | COMBINATION OF CELLULAR IMMUNOTHERAPY | CD47, IL2RA, IL2 | RAF1 470/4885BRAF 422/4885KDR 648/4885 |
| US-20050038080-A1 | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions | FLT4, FLT1, PDGFRB | RAF1 14/4885BRAF 7/4885KDR 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.